GlassScriptPhysician profile
Amanda Lee Ruxton
NPI 1457511321
$5,095.60
in general payments reported to CMS, 2019-2025
36 companies · $672 in 2025
The $672 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.47 · 2020: $686 · 2021: $1,072 · 2022: $751 · 2023: $890 · 2024: $953 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,494 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,494.10 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $801.66 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $626.05 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $562.82 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $388.13 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Mylan Specialty L.P. | $283.78 | 2021-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.17 | 2020-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $219.06 | 2020-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.24 | 2019-2023 | Tradjenta, Jardiance |
| Amgen INC. | $192.53 | 2021-2024 | Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $164.31 | 2022-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $155.45 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $134.29 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $125.46 | 2019-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $122.24 | 2020-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $108.53 | 2023-2024 | Nuedexta, Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $100.23 | 2020-2025 | Austedo, Austedo Xr, Austedo Xr |
| Pfizer INC. | $86.74 | 2019-2025 | |
| Amarin Pharma, INC. | $84.81 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $59.85 | 2024-2025 | Fanapt, Hetlioz |
| Biohaven Pharmaceuticals, INC. | $59.17 | 2021 | |
| Novartis Pharmaceuticals Corporation | $46.49 | 2020-2022 | |
| Viatris Specialty LLC | $45.17 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $44.56 | 2021-2022 | |
| Axsome Therapeutics, INC. | $39.49 | 2024-2025 | Auvelity |
| Exact Sciences Corporation | $37.65 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $23.15 | 2021 | |
| Genentech USA, INC. | $22.19 | 2020 | |
| Exeltis, USA INC. | $19.78 | 2023 | Slynd |
| Dexcom, INC. | $19.77 | 2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $18.56 | 2024 | Eliquis |
| Merck Sharp & Dohme LLC | $16.28 | 2020 | |
| Glaxosmithkline, LLC. | $15.68 | 2024 | Trelegy Ellipta |
| Ultragenyx Pharmaceutical INC. | $14.96 | 2020 | |
| Medtronic Minimed, INC. | $14.73 | 2019 | |
| Abbott Laboratories | $14.19 | 2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Ruxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.